Journal Mobile Options
Table of Contents
Vol. 25, No. 6, 2008
Issue release date: July 2008

Neuropsychiatric Correlates of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease

Skogseth R. · Mulugeta E. · Ballard C. · Rongve A. · Nore S. · Alves G. · Aarsland D.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The aim of this study was to explore the relationship between cerebrospinal fluid biomarkers and neuropsychiatric symptoms in people with Alzheimer’s disease. Psychosis, agitation, apathy and depression were assessed using standardised measures in 32 patients with mild Alzheimer’s disease. Methods: The levels of the 42-amino-acid form of β-amyloid (Aβ1–42), tau and p-tau (phosphorylated at threonine 181) were quantified using the conventional enzyme-linked immunosorbent assay method. Results: Our result shows that apathy is significantly correlated with tau and p-tau but not with Aβ1–42. There were no significant correlations between indices of psychosis/agitation,or depression and cerebrospinal fluid Aβ1–42, tau or p-tau concentrations. Conclusion: Our finding suggests that apathy is associated with the level of neurofibrillary tangles in people with mild Alzheimer’s disease. In contrast, the overall levels of neurofibrillary tangles or amyloid plaques do not seem to be associated with depression or psychosis, indicating that other brain changes contribute to these symptoms.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Blennow K, Hampel H: CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003;2:605–613.
  2. Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E, Teipel SJ, Graz C, Blennow K, Hampel H: Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 2005;65:1502–1503.
  3. Wallin AK, Blennow K, Andreasen N, Minthon L: CSF biomarkers for Alzheimer’s disease: levels of β-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 2006;21:131–138.
  4. Holmes C, Ballard C, Lehmann D, David Smith A, Beaumont H, Day IN, Nadeem Khan M, Lovestone S, McCulley M, Morris CM, Munoz DG, O’Brien K, Russ C, Del Ser T, Warden D: Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 2005;76:640–643.
  5. Wilson RS, Tang Y, Aggarwal NT, Gilley DW, McCann JJ, Bienias JL, Evans DA: Hallucinations, cognitive decline, and death in Alzheimer’s disease. Neuroepidemiology 2006;26:68–75.
  6. Stern Y, Albert M, Brandt J, Jacobs DM, Tang MX, Marder K, Bell K, Sano M, Devanand DP, Bylsma F: Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer’s disease: prospective analyses from the Predictors Study. Neurology 1994;44:2300–2307.
  7. Cannon-Spoor HE, Levy JA, Zubenko GS, Zubenko WW, Cohen RM, Mirza N, Putnam K, Sunderland T: Effects of previous major depressive illness on cognition in Alzheimer disease patients. Am J Geriatr Psychiatry 2005;13:312–318.
  8. Scarmeas N, Brandt J, Blacker D, Albert M, Hadjigeorgiou G, Dubois B, Devanand D, Honig L, Stern Y: Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol 2007;64:1755–1761.
  9. Teng E, Lu PH, Cummings JL: Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer’s disease. Dement Geriatr Cogn Disord 2007;24:253–259.
  10. Tekin S, Mega MS, Masterman DM, Chow T, Garakian J, Vinters HV, Cummings JL: Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001;49:355–361.
  11. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL: Neuropathologic correlates of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2006;21:144–147.
  12. Farber NB, Rubin EH, Newcomer JW, Kinscherf DA, Miller JP, Morris JC, Olney JW, McKeel DW Jr: Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry 2000;57:1165–1173.
  13. Ballard CG, Jacoby R, Del Ser T, Khan MN, Munoz DG, Holmes C, Nagy Z, Perry EK, Joachim C, Jaros E, O’Brien JT, Perry RH, McKeith IG: Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry 2004;161:843–849.
  14. Ballard C, Walker M: Neuropsychiatric aspects of Alzheimer’s disease. Curr Psychiatry Rep 1999;1:49–60.
  15. Ballard C, Waite J: The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006;1:CD003476.
  16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  17. Jorm AF, Jacomb PA: The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015–1022.
  18. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.
  19. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.
  20. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG: Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992;4:134–139.
  21. Apostolova LG, Akopyan GG, Partiali N, Steiner CA, Dutton RA, Hayashi KM, Dinov ID, Toga AW, Cummings JL, Thompson PM: Structural correlates of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2007;24:91–97.
  22. Aarsland D, Sharp S, Ballard C: Psychiatric and behavioral symptoms in Alzheimer’s disease and other dementias: etiology and management. Curr Neurol Neurosci Rep 2005;5:345–354.
  23. Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL: Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 2007;64:1015–1020.
  24. Lanctôt KL, Moosa S, Herrmann N, Leibovitch FS, Rothenburg L, Cotter A, Black SE: A SPECT study of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2007;24:65–72.
  25. Blennow K: Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx. 2004;1:213–225.
  26. Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J, Alafuzoff I, Riekkinen P Sr, Soininen H: The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer’s disease. Neuroreport 1997;8:3961–3963.
  27. Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H: CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 2006;129:3035–3041.
  28. Buerger K, Alafuzoff I, Ewers M, Pirttilä T, Zinkowski R, Hampel H: No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 2007;130:e82.
  29. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP: No association of CSF biomarkers with APOEε4, plaque and tangle burden in definite Alzheimer’s disease. Brain 2007;130:2320–2326.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50